Increased urinary F2-isoprostanes levels in the patients with Alzheimer's disease

被引:35
|
作者
Kim, KM
Jung, BH
Paeng, KJ
Kim, I
Chung, BC
机构
[1] Korea Inst Sci & Technol, Bioanal & Biotransformat Res Ctr, Seoul 130650, South Korea
[2] Yonsei Univ, Dept Chem, Wonju 220710, South Korea
[3] Gongju Geriatr Hosp, Chungnam, Gongju City, South Korea
关键词
F-2-isoprostanes; Alzheimer's disease; oxidative stress; gas chromatography-mass spectrometry;
D O I
10.1016/j.brainresbull.2004.04.016
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Isoprostanes, novel markers of oxidative injury, are generated by the free radical-mediated peroxidation of arachidonic acid (AA). They are thought to be important in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD). Using gas chromatography-mass spectrometry (GC-MS), we investigated the alteration of urinary F-2-isoprostanes in AD patients compared to that of healthy subjects. Our results show that the levels of urinary F-2-isoprostanes, sum of the prostaglandin F-2alpha isomer; prostaglandin F-2alpha (PGF(2alpha)), prostaglandin F-2beta (PGF(2beta)), and 8-isoprostaglandin F-2alpha (8-isoPGF(2alpha)), significantly increased in AD patients (P < 0.05). The concentration of urinary 8-isoPGF(2alpha), one of the biomarkers of oxidative stress, was not significantly different between 34 AD patients and 20 age-matched controls (P > 0.05). The PGF(2alpha), formed by endoperoxide reductase from PGH(2), was significantly increased in AD patients, when compared with the levels of the normal controls (P < 0.05). The PGF(2alpha), an enzymatic product of arachidonic acid, may affect the pathogenesis of AD. In addition, urinary F-2-isoprostanes can play an important role as a biomarker in AD. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:47 / 51
页数:5
相关论文
共 50 条
  • [1] Increased urinary F2-isoprostanes in patients with Crohn's disease
    Cracowski, JL
    Bonaz, B
    Bessard, G
    Bessard, J
    Anglade, C
    Fournet, J
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (01): : 99 - 103
  • [2] Enhanced urinary F2-isoprostanes in patients with Crohn's disease
    Bonaz, B
    Cracowski, JL
    Bessard, J
    Anglade, C
    Bessard, G
    Fournet, J
    [J]. GASTROENTEROLOGY, 2001, 120 (05) : A186 - A186
  • [3] Biomarkers of Alzheimer's disease: F2-isoprostanes
    Pratico, D
    [J]. NEUROBIOLOGY OF AGING, 2004, 25 : S5 - S5
  • [4] Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease
    Montine, TJ
    Quinn, JF
    Milatovic, D
    Silbert, LC
    Dang, T
    Sanchez, S
    Terry, E
    Roberts, LJ
    Kaye, JA
    Morrow, JD
    [J]. ANNALS OF NEUROLOGY, 2002, 52 (02) : 175 - 179
  • [5] No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls
    Montine, TJ
    Shinobu, L
    Montine, KS
    Roberts, LJ
    Kowall, NW
    Beal, MF
    Morrow, JD
    [J]. ANNALS OF NEUROLOGY, 2000, 48 (06) : 950 - 950
  • [6] Increased F2-isoprostanes in Alzheimer's disease:: evidence for enhanced lipid peroxidation in vivo
    Praticò, D
    Lee, VMY
    Trojanowski, JQ
    Rokach, J
    Fitzgerald, GA
    [J]. FASEB JOURNAL, 1998, 12 (15): : 1777 - 1783
  • [7] F2-isoprostanes as biomarkers of late-onset Alzheimer's disease
    Montine, Thomas J.
    Quinn, Joseph
    Kaye, Jeffrey
    Morrow, Jason D.
    [J]. JOURNAL OF MOLECULAR NEUROSCIENCE, 2007, 33 (01) : 114 - 119
  • [8] F2-Isoprostanes as Biomarkers of Late-onset Alzheimer’s Disease
    Thomas J. Montine
    Joseph Quinn
    Jeffrey Kaye
    Jason D. Morrow
    [J]. Journal of Molecular Neuroscience, 2007, 33 : 114 - 119
  • [9] Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimer's Disease as Identified by Biomarkers
    Montine, Thomas J.
    Peskind, Elaine R.
    Quinn, Joseph F.
    Wilson, Angela M.
    Montine, Kathleen S.
    Galasko, Douglas
    [J]. NEUROMOLECULAR MEDICINE, 2011, 13 (01) : 37 - 43
  • [10] Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimer’s Disease as Identified by Biomarkers
    Thomas J. Montine
    Elaine R. Peskind
    Joseph F. Quinn
    Angela M. Wilson
    Kathleen S. Montine
    Douglas Galasko
    [J]. NeuroMolecular Medicine, 2011, 13 : 37 - 43